BACKGROUND: To present a case report of a patient with a mixed choroidal neovascular membrane (CNV) with an asymmetric response to ranibizumab diagnosed on optical coherence tomography angiography (OCTa). CASE PRESENTATION: A 61-year-old male was referred to our department in September 2017 due to decreased vision in his left eye. Best-corrected visual acuity (BCVA) was 43 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye. Macular edema was present in the left eye, and a mixed CNV was identified on the OCTa. Therapy with intravitreal ranibizumab was commenced. After 5 ranibizumab injections, the BCVA was 42 ETDRS letters, and considerable intraretinal edema was still present. OCTa showed a resolution of the type 2 lesion of the mixed CNV; however, the type 1 lesion had continued to grow. The patient was then switched to intravitreal aflibercept. After 3 monthly aflibercept injections, the BCVA improved to 53 ETDRS letters, and a reduction of the edema was observed on the optical coherence tomography (OCT). OCTa showed a decrease in both the area and vessel density in the type 1 lesion of the CNV. Therapy with aflibercept was continued; however, while the intraretinal edema continued to improve, atrophy developed in the macula and the BCVA worsened to 43 ETDRS letters. CONCLUSIONS: Ranibizumab nonresponse in a neovascular age-related macular degeneration is not uncommon. However, to our knowledge, this is the first described case of an asymmetric response to ranibizumab in a mixed CNV. While the type 2 lesion of the CNV reacted swiftly to the ranibizumab therapy, the type 1 lesion continued to grow. As with some other cases of ranibizumab resistance, switching to aflibercept proved effective.

Department of Ophthalmology 3rd Faculty of Medicine Charles University Prague and University Hospital Kralovske Vinohrady Srobarova 1150 50 Prague 100 34 Czech Republic

Zobrazit více v PubMed

Bressler NM, Bressler SB, et al. Chapter 66 - Neovascular (exudative or “wet”) age-related macular degeneration A2 - Ryan, Stephen J. In: Sadda SR, Hinton DR, Schachat AP, Sadda SR, Wilkinson CP, Wiedemann P, et al., editors. Retina Fifth Ed. London: W.B. Saunders; 2013. p. 1183–212.

Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16. doi: 10.1056/NEJMoa042760. PubMed DOI

Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48. doi: 10.1016/j.ophtha.2012.09.006. PubMed DOI

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006;355:1419–31. doi: 10.1056/NEJMoa054481. PubMed DOI

Stepanov A, Nemcansky J, Veith M, Manethova K, Stredova M, Pencak M, et al. Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic. Eur J Ophthalmol. 2020 doi: 10.1177/1120672120971190. PubMed DOI

Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29:723–31. doi: 10.1097/IAE.0b013e3181a2c1c3. PubMed DOI PMC

Doguizi S, Ozdek S, Yuksel S. Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration. Int J Ophthalmol. 2015;8:846–8. PubMed PMC

Pinheiro-Costa J, Costa JM, Beato JN, Freitas-da-Costa P, Brandao E, Falcao MS, et al. Switch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practice. Ophthalmologica. 2015;233:155–61. doi: 10.1159/000381221. PubMed DOI

Shiragami C, Ono A, Kobayashi M, Manabe S, Yamashita A, Shiraga F. Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration. Medicine. 2014;93:e116. doi: 10.1097/MD.0000000000000116. PubMed DOI PMC

Kim JM, Cho HJ, Kim Y, Jung SH, Lee DW, Kim JW. Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis. Semin Ophthalmol. 2019;34:168–76. doi: 10.1080/08820538.2019.1620791. PubMed DOI

Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, et al. Aflibercept Therapy for Exudative Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab. Am J Ophthalmol. 2013;156:15–22.e1. doi: 10.1016/j.ajo.2013.02.017. PubMed DOI

Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013;120:115–21. doi: 10.1016/j.ophtha.2012.10.006. PubMed DOI

Forooghian F, Chew EY, Meyerle CB, Cukras C, Wong WT. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol. 2011;89:206–7. doi: 10.1111/j.1755-3768.2009.01773.x. PubMed DOI

Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168:2036–53. doi: 10.2353/ajpath.2006.050588. PubMed DOI PMC

Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98:813–25. doi: 10.1136/bjophthalmol-2013-304019. PubMed DOI

Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85. doi: 10.1007/s10456-011-9249-6. PubMed DOI PMC

Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ophthalmology. 2014;121:193–201. doi: 10.1016/j.ophtha.2013.08.011. PubMed DOI